H Cortes-Funes
Overview
Explore the profile of H Cortes-Funes including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
110
Citations
2308
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al.
J Clin Oncol
. 2023 Nov;
41(33):5080-5089.
PMID: 37967516
Purpose: In a previous study of treatment for advanced colorectal cancer, the LV5FU2 regimen, comprising leucovorin (LV) plus bolus and infusional fluorouracil (5FU) every 2 weeks, was superior to the...
2.
Salazar R, Cortes-Funes H, Casado E, Pardo B, Lopez-Martin A, Cuadra C, et al.
Cancer Chemother Pharmacol
. 2013 May;
72(1):75-83.
PMID: 23645288
Purpose: Kahalalide F (KF) is a dehydroaminobutyric acid-containing peptide from marine origin with activity against several human malignant cell lines. This dose-escalating phase I clinical trial evaluated the maximum tolerated...
3.
Manso L, Valdiviezo N, Sepulveda J, Ciruelos E, Mendiola C, Ghanem I, et al.
Clin Transl Oncol
. 2012 Dec;
15(6):467-71.
PMID: 23263907
Purpose: Metronomic administration of the same chemotherapy agents (lower doses with closer intervals) may optimize their antiangiogenic properties. The aim of our study was to determine the efficacy and safety...
4.
Yap T, Cortes-Funes H, Shaw H, Rodriguez R, Olmos D, Lal R, et al.
Br J Cancer
. 2012 Apr;
106(8):1379-85.
PMID: 22491421
Background: PM00104 binds guanines at DNA minor grooves, impacting DNA replication and transcription. A phase I study was undertaken to investigate safety, dose-limiting toxicities (DLTs), recommended phase II dose (RP2D),...
5.
Hitt R, Irigoyen A, Cortes-Funes H, Grau J, Garcia-Saenz J, Cruz-Hernandez J
Ann Oncol
. 2011 Aug;
23(4):1016-22.
PMID: 21865152
Background: The efficacy and safety of a novel combination of weekly paclitaxel and the epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab for the first-line treatment of recurrent and/or metastatic...
6.
Cortes-Funes H, Ghanem I
Expert Rev Anticancer Ther
. 2011 Feb;
11(2):165-8.
PMID: 21342034
Evaluation of: Kaufmann M, Maass N, Costa SD et al. First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: results of the MONICA trial. Eur....
7.
Garcia-Escobar I, Sepulveda J, Castellano D, Cortes-Funes H
Crit Rev Oncol Hematol
. 2010 Dec;
80(1):100-13.
PMID: 21146422
Chronic lymphocytic leukaemia (CLL) is a common, often incurable low-grade-B lymphoproliferative disorder. For many years, chlorambucil alone or with steroids has been the drug of choice in treatment-naive patients. Purine...
8.
Smith I, Pierga J, Biganzoli L, Cortes-Funes H, Thomssen C, Pivot X, et al.
Ann Oncol
. 2010 Sep;
22(3):595-602.
PMID: 20819780
Background: First-line bevacizumab combined with chemotherapy significantly improves efficacy versus chemotherapy alone in human epidermal growth factor receptor 2 (HER2)-negative locally recurrent or metastatic breast cancer (LR/mBC). This large, open-label...
9.
Ciruelos E, Cortes J, Cortes-Funes H, Mayordomo J, Bermejo B, Ojeda B, et al.
Ann Oncol
. 2009 Nov;
21(7):1442-1447.
PMID: 19940004
Background: On the basis of clinical activity of capecitabine and gemcitabine for metastatic breast cancer, we carried out a multicenter phase II clinical trial on the combination of these two...
10.
Garrido-Laguna I, Amador M, Ruiz J, Cortes-Funes H
Clin Transl Oncol
. 2009 Mar;
11(3):183-5.
PMID: 19293057
Acute ischaemic cerebrovascular attack may be an underreported complication related to chemotherapy. We report here the case of a patient with acute ischaemic cerebrovascular attack, immediately after administration of a...